Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells

David A. DavisHIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USACorrespondence[email protected]
View further author information

Prabha ShresthaHIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAView further author information

Ashley I. AisaborHIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAView further author information

Alexandra StreamHIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAView further author information

Veronica GalliVaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAView further author information

Cynthia A. Pise-MasisonVaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAView further author information

Takanobu TagawaHIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAView further author information

Joseph M. ZiegelbauerHIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAView further author information

Genoveffa FranchiniVaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAView further author information

Robert YarchoanHIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Your download is now in progress and you may close this window